Dogwood Secures FDA IND Nod for SP16 Pain Therapy

Alpharetta, Georgia, U.S. | April 15, 2026

Dogwood Therapeutics has announced a major regulatory milestone with the U.S. Food and Drug Administration (FDA) acceptance of its Investigational New Drug (IND) application for SP16, a novel therapy targeting chemotherapy-induced pain and peripheral neuropathy (CIPPN). This development marks a critical step in advancing non-opioid pain management therapies into clinical development and underscores the growing importance of innovative treatments addressing the long-term side effects of cancer therapies. The IND acceptance enables Dogwood to initiate human clinical studies, positioning SP16 as a promising candidate in the company’s expanding pipeline of first-in-class therapeutics targeting neuropathic pain and nerve damage.

FDA IND Acceptance Accelerates Clinical Development Pathway

The FDA’s acceptance of the IND application for SP16 represents a key regulatory milestone, allowing Dogwood Therapeutics and its partner Serpin Pharma to move forward with a Phase 1b clinical trial expected to begin in mid-2026. The study will be conducted at the University of Virginia and is fully funded by the National Cancer Institute (NCI), reflecting strong institutional support for this innovative therapeutic approach.

IND acceptance confirms that the therapy has met critical preclinical safety, manufacturing, and regulatory requirements, including GLP toxicology data, CMC readiness, and GMP manufacturing standards, all essential for progressing into human trials. This milestone significantly strengthens Dogwood’s clinical pipeline and highlights regulatory confidence in SP16’s potential to address a major unmet need in oncology supportive care.

Novel Mechanism Targets Inflammation and Nerve Repair

SP16 is a first-in-class LRP1 agonist therapy administered via intravenous infusion, designed to address both the inflammatory and degenerative components of chemotherapy-induced neuropathy. The therapy demonstrates dual mechanisms of action, including reduction of pro-inflammatory cytokines such as IL-6, IL-8, IL-1β, and TNF-alpha, as well as activation of signaling pathways like pAKT and pERK, which are critical for tissue repair, cell survival, and nerve regeneration.

This combined approach positions SP16 as a potentially transformative treatment capable of not only alleviating pain but also repairing nerve damage and improving functional outcomes in cancer patients. Given that CIPPN affects approximately 30–40% of patients following chemotherapy, often with long-term debilitating symptoms such as numbness, tingling, and impaired motor function, the need for effective therapies remains significant.

Addressing Unmet Need in Oncology Supportive Care

Chemotherapy-induced neuropathy remains one of the most challenging side effects of cancer treatment, with limited effective treatment options currently available. Existing therapies primarily focus on symptom management rather than addressing underlying nerve damage. SP16 aims to fill this gap by offering a non-opioid, disease-modifying approach that targets both inflammation and tissue repair. The therapy complements Dogwood’s broader pipeline, including its lead candidate Halneuron®, which is already in Phase 2b development. Together, these programs demonstrate the company’s strategic focus on developing innovative, non-addictive therapies for pain and neurological conditions, aligning with global efforts to reduce reliance on opioid-based treatments.

Strategic and Regulatory Implications for Future Development

The IND acceptance for SP16 not only advances Dogwood’s clinical development strategy but also reflects broader industry trends toward precision medicine and targeted therapeutic mechanisms. With regulatory approval to begin clinical trials, the company is well-positioned to generate early human data that could support further development and potential regulatory submissions.

The collaboration with Serpin Pharma and funding support from the NCI further strengthen the program’s credibility and execution capabilities. As SP16 progresses through clinical trials, it has the potential to reshape the treatment landscape for chemotherapy-induced neuropathy, offering new hope for patients experiencing long-term side effects of cancer therapy.

The FDA acceptance of the SP16 IND application marks a pivotal milestone for Dogwood Therapeutics and highlights the growing importance of innovative, non-opioid therapies in oncology supportive care. By advancing a therapy that addresses both pain and nerve damage, the company is contributing to the development of next-generation treatments that improve patient quality of life. As clinical trials commence, SP16’s progress will be closely watched as a potential breakthrough in the management of chemotherapy-induced neuropathy, reinforcing the role of regulatory milestones and clinical innovation in shaping the future of pharmaceutical development.

Source: Dogwood Therapeutics press release